Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Discordance, accuracy and reproducibility study of pathologists’ diagnosis of melanoma and melanocytic tumorsIn: Nature Communications, Jg. 16, 2025, Nr. 1, 789DOI (Open Access)
-
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanomaIn: Journal of the European Academy of Dermatology and Venereology, Jg. 39, 2025, Nr. 11, S. 1975 – 1986DOI (Open Access)
-
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy : A multicenter study on 2419 patients from the prospective skin cancer registry ADORegIn: European Journal of Cancer (EJC), Jg. 214, 2025, 115159DOI (Open Access)
-
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients with Stage III MelanomaIn: Journal of Clinical Oncology (JCO), Jg. 43, 2025, Nr. 25, S. 2793 – 2805
-
Outcome of systemic therapy in patients with advanced rare skin cancers : A retrospective multicenter DeCOG study of 209 patientsIn: European Journal of Cancer (EJC), Jg. 228, 2025, 115750DOI (Open Access)
-
Retraction note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceIn: Nature, Jg. 647, 2025, S. 544DOI (Open Access)
-
Targeted therapy for rare BRAF-mutated melanoma : Updated multicenter analysis and launch of a publicly accessible online outcome databaseIn: European Journal of Cancer (EJC), Jg. 228, 2025, 115703
-
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockadeIn: European Journal of Cancer (EJC), Jg. 200, 2024, 113536DOI (Open Access)
-
Dermatologist-like explainable AI enhances trust and confidence in diagnosing melanomaIn: Nature Communications, Jg. 15, 2024, Nr. 1, 524DOI (Open Access)
-
Federated Learning for Decentralized Artificial Intelligence in Melanoma DiagnosticsIn: JAMA Dermatology, Jg. 160, 2024, Nr. 3, S. 303 – 311DOI (Open Access)
-
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanomaIn: Science Advances, Jg. 10, 2024, Nr. 48, eadp4670DOI (Open Access)
-
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma : A multicenter study on 1383 patients of the prospective DeCOG registry ADORegIn: International Journal of Cancer, Jg. 155, 2024, Nr. 10, S. 1808 – 1823DOI (Open Access)
-
Loss of p14 diminishes immunogenicity in melanoma via non‐canonical Wnt signaling by reducing the peptide surface densityIn: Molecular Oncology, Jg. 18, 2024, Nr. 10, S. 2449 – 2470DOI (Open Access)
-
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity : a multicenter case seriesIn: Journal for ImmunoTherapy of Cancer, Jg. 12, 2024, Nr. 1, e008232DOI (Open Access)
-
Prospective multicenter study using artificial intelligence to improve dermoscopic melanoma diagnosis in patient careIn: Communications Medicine, Jg. 4, 2024, Nr. 1, 177DOI (Open Access)
-
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O) : disease-free survival results from a randomised, open-label, phase 2 trialIn: Lancet, Jg. 402, 2023, Nr. 10404, S. 798 – 808
-
Adjuvant treatment and outcome of stage III melanoma patients : Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyIn: European Journal of Cancer (EJC), Jg. 191, 2023, 112957
-
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer, Jg. 11, 2023, Nr. 4DOI (Open Access)
-
Clinical, histopathological and molecular features of dedifferentiated melanomas : An EORTC Melanoma Group Retrospective AnalysisIn: European Journal of Cancer (EJC), Jg. 187, 2023, S. 7 – 14DOI (Open Access)
-
Tebentafusp in Patients with Metastatic Uveal Melanoma : A Real-Life Retrospective Multicenter StudyIn: Cancers, Jg. 15, 2023, Nr. 13, 3430DOI (Open Access)
-
Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy : A multicenter study from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer, Jg. 11, 2023, Nr. 9, e007630DOI (Open Access)
-
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : Final results of a randomised, double-blind, phase 2 trialIn: Lancet, Jg. 400, 2022, Nr. 10358, S. 1117 – 1129
-
Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced MelanomaIn: Cancers, Jg. 14, 2022, Nr. 9, 2294DOI (Open Access)
-
Corrigendum to “Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group Molecular Diagnostics and Therapy”In: European Journal of Cancer (EJC), Jg. 162, 2022, S. 245 – 246
-
Explainable artificial intelligence in skin cancer recognition : A systematic reviewIn: European Journal of Cancer (EJC), Jg. 167, 2022, S. 54 – 69DOI (Open Access)
-
Genetic characterization of advanced conjunctival melanoma and response to systemic treatmentIn: European Journal of Cancer (EJC), Jg. 166, 2022, S. 60 – 72
-
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma : A multicenter study of the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer, Jg. 10, 2022, Nr. 11, e005930DOI (Open Access)
-
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma : An evaluation of the multicenter prospective skin cancer registry ADOREGIn: European Journal of Cancer (EJC), Jg. 167, 2022, S. 32 – 41DOI (Open Access)
-
Model soups improve performance of dermoscopic skin cancer classifiersIn: European Journal of Cancer (EJC), Jg. 173, 2022, S. 307 – 316DOI (Open Access)
-
A benchmark for neural network robustness in skin cancer classificationIn: European Journal of Cancer (EJC), Jg. 155, 2021, S. 191 – 199DOI (Open Access)
-
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinomaIn: Cancer Immunology, Immunotherapy, Jg. 70, 2021, Nr. 7, S. 2087 – 2093DOI (Open Access)
-
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastasesIn: European Journal of Cancer (EJC), Jg. 152, 2021, S. 139 – 154
-
Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classificationIn: European Journal of Cancer (EJC), Jg. 149, 2021, S. 94 – 101DOI (Open Access)
-
Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell responseIn: Proceedings of the National Academy of Sciences of the United States of America (PNAS), Jg. 118, 2021, Nr. 43, e2102849118DOI, Online Volltext (Open Access)
-
Factors influencing the adjuvant therapy decision : Results of a real-world multicenter data analysis of 904 melanoma patientsIn: Cancers, Jg. 13, 2021, Nr. 10, S. 2319DOI, Online Volltext (Open Access)
-
Integrating patient data into skin cancer classification using convolutional neural networks : Systematic reviewIn: Journal of Medical Internet Research (JMIR), Jg. 23, 2021, Nr. 7, e20708DOI (Open Access)
-
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionIn: European Journal of Cancer (EJC), Jg. 148, 2021, S. 61 – 75
-
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries : A multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)In: Journal of Cancer Research and Clinical Oncology, Jg. 147, 2021, Nr. 6, S. 1763 – 1771DOI (Open Access)
-
Robustness of convolutional neural networks in recognition of pigmented skin lesionsIn: European Journal of Cancer (EJC), Jg. 145, 2021, S. 81 – 91DOI (Open Access)
-
Skin cancer classification via convolutional neural networks : Systematic review of studies involving human expertsIn: European Journal of Cancer (EJC), Jg. 156, 2021, S. 202 – 216DOI (Open Access)
-
Surveillance of patients with conjunctival melanoma in German-speaking countries : A multinational survey of the German dermatologic cooperative oncology groupIn: European Journal of Cancer (EJC), Jg. 143, 2021, S. 43 – 45
-
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : A randomised, double-blind, placebo-controlled, phase 2 trialIn: Lancet, Jg. 395, 2020, Nr. 10236, S. 1558 – 1568
-
Artificial Intelligence and Its Effect on Dermatologists' Accuracy in Dermoscopic Melanoma Image Classification : Web-Based Survey StudyIn: Journal of Medical Internet Research (JMIR), Jg. 22, 2020, Nr. 9, S. e18091DOI (Open Access)
-
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine, Jg. 26, 2020, Nr. 7, S. 1147DOI (Open Access)
-
Conceptual framework for precision cancer medicine in Germany : Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy’In: European Journal of Cancer (EJC), Jg. 135, 2020, S. 1 – 7
-
Effects of Label Noise on Deep Learning-Based Skin Cancer ClassificationIn: Frontiers in Medicine, Jg. 7, 2020, S. 177DOI (Open Access)
-
GNAQ and GNA11 mutant nonuveal melanoma : A subtype distinct from both cutaneous and uveal melanomaIn: British Journal of Dermatology: BJD, Jg. 183, 2020, Nr. 5, S. 928 – 939DOI (Open Access)
-
Integrated molecular drivers coordinate biological and clinical states in melanomaIn: Nature Genetics, Jg. 52, 2020, Nr. 12, S. 1373 – 1383DOI, Online Volltext (Open Access)
-
Localization of PD-L1 on single cancer cells by iSERS microscopy with Au/Au core/satellite nanoparticlesIn: Journal of Biophotonics, Jg. 13, 2020, Nr. 3, e201960034DOI (Open Access)
-
S3 Guideline for the Diagnosis, Therapy and Follow‐Up of Malignant MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG), Jg. 18, 2020, Nr. 10, S. 1079 – 1208DOI (Open Access)
-
A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification taskIn: European Journal of Cancer (EJC), Jg. 111, 2019, S. 148 – 154DOI (Open Access)
-
Chemoirradiated neutrophils and T cells differentially affect immune functions of APCsIn: Journal of Leukocyte Biology (JLB), Jg. 106, 2019, Nr. 2: Special Focus Issue: Tissue Phagocyte Heterogeneity in Health and Disease (AAI/SLB), S. 481 – 493
-
Comparing artificial intelligence algorithms to 157 German dermatologists : the melanoma classification benchmarkIn: European Journal of Cancer (EJC), Jg. 111, 2019, S. 30 – 37DOI (Open Access)
-
Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification taskIn: European Journal of Cancer (EJC), Jg. 113, 2019, S. 47 – 54DOI (Open Access)
-
Deep neural networks are superior to dermatologists in melanoma image classificationIn: European Journal of Cancer (EJC), Jg. 119, 2019, S. 11 – 17DOI (Open Access)
-
Distinct immunogenomic properties of melanomas with stable disease as best response to immune checkpoint blockade (ICB)In: Journal of Clinical Oncology (JCO), Jg. 37, 2019, Nr. 15_Suppl, S. 2515 – 2515
-
Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanomaIn: European Journal of Cancer (EJC), Jg. 116, 2019, S. 207 – 215
-
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysisIn: Cancer Immunology, Immunotherapy, Jg. 68, 2019, Nr. 5, S. 765 – 772DOI, Online Volltext (Open Access)
-
High PD-1 or PD-L1 Concentrations in the Serum of Melanoma Patients are predictive for reduced Therapeutic Success of PD-1 InhibitionIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG), Jg. 17, 2019, Nr. Suppl. 5, S. 7 – 7
-
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine, Jg. 25, 2019, Nr. 12, S. 1916 – 1927DOI (Open Access)
-
Prediction of melanoma evolution in melanocytic nevi via artificial intelligence : A call for prospective dataIn: European Journal of Cancer (EJC), Jg. 119, 2019, S. 30 – 34DOI (Open Access)
-
Superior skin cancer classification by the combination of human and artificial intelligenceIn: European Journal of Cancer (EJC), Jg. 120, 2019, S. 114 – 121DOI (Open Access)
-
Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networksIn: European Journal of Cancer (EJC), Jg. 119, 2019, S. 57 – 65DOI (Open Access)
-
Targeted Therapy in Advanced Melanoma With Rare BRAF MutationsIn: Journal of Clinical Oncology (JCO), Jg. 37, 2019, Nr. 33, S. 3142 – 3151DOI (Open Access)
-
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeIn: Cell, Jg. 175, 2018, Nr. 4, S. 984 – 997.e24DOI (Open Access)
-
Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-Cell populationsIn: Clinical Cancer Research, Jg. 24, 2018, Nr. 21, S. 5347 – 5356DOI, Online Volltext (Open Access)
-
Can checkpoint inhibitor therapy improve response to chemotherapy?In: Journal of Cancer Research and Clinical Oncology, Jg. 144, 2018, Nr. 1, S. 183 – 185
-
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 BlockadeIn: Cell, Jg. 173, 2018, Nr. 3, S. 624 – 633.e8DOI, Online Volltext (Open Access)
-
Evolution of melanoma cross-resistance to CD8⁺ T cells and MAPK inhibition in the course of BRAFi treatmentIn: OncoImmunology, Jg. 7, 2018, Nr. 8, e1450127DOI, Online Volltext (Open Access)
-
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumorsIn: Nature Genetics, Jg. 50, 2018, Nr. 9, S. 1271 – 1281DOI, Online Volltext (Open Access)
-
NF1 mutations in conjunctival melanomaIn: British Journal of Cancer (BJC), Jg. 118, 2018, Nr. 9, S. 1243 – 1247DOI (Open Access)
-
Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockadeIn: European Journal of Cancer (EJC), Jg. 99, 2018, S. 58 – 65
-
Acquired IFNγ 3 resistance impairs anti-Tumor immunity and gives rise to T-cell-resistant melanoma lesionsIn: Nature Communications, Jg. 8, 2017, 15440DOI (Open Access)
-
Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue neviIn: Modern Pathology, Jg. 30, 2017, Nr. 3, S. 350 – 356DOI, Online Volltext (Open Access)
-
Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitisIn: European Journal of Cancer (EJC), Jg. 86, 2017, S. 248 – 256
-
Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris MelanomaIn: Investigative Ophthalmology & Visual Science (IOVS), Jg. 58, 2017, Nr. 9, S. 3464 – 3470DOI (Open Access)
-
Immunotherapy in melanoma : Recent advances and future directionsIn: European Journal of Surgical Oncology, Jg. 43, 2017, Nr. 3, S. 604 – 611
-
Next-Generation Sequencing to Guide Treatment of Advanced MelanomaIn: American Journal of Clinical Dermatology, Jg. 18, 2017, Nr. 3, S. 303 – 310
-
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patientsIn: European Journal of Cancer (EJC), Jg. 73, 2017, S. 61 – 70DOI, Online Volltext (Open Access)
-
SF3B1 and BAP1 mutations in blue nevus-like melanomaIn: Modern Pathology, Jg. 30, 2017, Nr. 7, S. 928 – 939DOI, Online Volltext (Open Access)
-
Baseline Biomarkers for Outcome of Melanoma Patients Treated with PembrolizumabIn: Clinical Cancer Research, Jg. 22, 2016, Nr. 22, S. 5487 – 5496DOI (Open Access)
-
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabIn: Clinical Cancer Research, Jg. 22, 2016, Nr. 12, S. 2908 – 2918DOI (Open Access)
-
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipientIn: European Journal of Cancer (EJC), Jg. 67, 2016, S. 66 – 72
-
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeIn: Science, Jg. 351, 2016, Nr. 6280, S. 1463 – 1469
-
Granulocytic myeloid-derived suppressor cells in peripheral blood of patients with cutaneous melanomaIn: International Immunology, Jg. 28, 2016, Nr. 2, S. 99
-
Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma : a retrospective multicenter analysisIn: Cancer Immunology, Immunotherapy, Jg. 65, 2016, Nr. 8, S. 951 – 959
-
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with IpilimumabIn: Clinical Cancer Research, Jg. 22, 2016, Nr. 19, S. 4848 – 4858
-
Medikamentöse Therapie des metastasierten malignen MelanomsIn: Arzneimitteltherapie (AMT), Jg. 34, 2016, Nr. 1-2, S. 14 – 22
-
Metastatic malignant melanoma with complete loss of differentiation markers (undifferentiated/dedifferentiated melanoma) : Analysis of 14 patients emphasizing phenotypic plasticity and the value of molecular testing as surrogate diagnostic markerIn: The American Journal of Surgical Pathology, Jg. 40, 2016, Nr. 2, S. 181 – 191
-
Molecular features of response to anti-PD-1 therapyIn: Chinese Clinical Oncology, Jg. 5, 2016, Nr. 6, S. 74DOI (Open Access)
-
Molekulare und immunhistochemische Diagnostik beim MelanomIn: Der Hautarzt, Jg. 67, 2016, Nr. 7, S. 511 – 518
-
Oncogene Status of an Interdigitating Dendritic Cell Sarcoma : Recurrent Mutations in NF1, TP53, and ARID2 Shared With MelanomaIn: The American Journal of Surgical Pathology, Jg. 40, 2016, Nr. 12, S. 1721 – 1723
-
Oncogene status as a diagnostic tool in ocular and cutaneous melanomaIn: European Journal of Cancer (EJC), Jg. 57, 2016, S. 112 – 117
-
Perspectives for immunotherapy in endocrine cancerIn: Endocrine-Related Cancer, Jg. 23, 2016, Nr. 10, S. R469 – 84
-
Phenotypic characterization and prognostic impact of circulating γδ and αβ T-cells in metastatic malignant melanomaIn: International Journal of Cancer, Jg. 138, 2016, Nr. 3, S. 698 – 704DOI (Open Access)
-
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabIn: European Journal of Cancer (EJC), Jg. 64, 2016, S. 116 – 126DOI, Online Volltext (Open Access)
-
Round Table - new concept of the Arbeitsgemeinschaft Dermatologische Forschung to foster regional exchange between young clinician scientists in dermatologyIn: Experimental Dermatology, Jg. 25, 2016, Nr. 10, S. 827 – 828
-
Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous systemIn: Journal of Neuro-Oncology, Jg. 127, 2016, Nr. 3, S. 435 – 444DOI, Online Volltext (Open Access)
-
Type i IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and humanIn: International Journal of Cancer, Jg. 138, 2016, Nr. 8, S. 1982 – 1993DOI (Open Access)
-
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceIn: Nature, Jg. 532, 2016, Nr. 7598, S. 250 – 254DOI, Online Volltext (Open Access)
-
Analysis of SDHD promoter mutations in various types of melanomaIn: OncoTarget, Jg. 6, 2015, Nr. 28, S. 25868 – 25882DOI (Open Access)
-
Analysis of SDHD promoter mutations in various types of melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG), Jg. 13, 2015, Nr. Suppl. 2, S. 11
-
Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of InfectionIn: PLoS ONE, Jg. 10, 2015, Nr. 4, S. e0124590DOI (Open Access)
-
Frequent TERT Promoter Mutations in Ocular Surface Squamous NeoplasiaIn: Investigative Ophthalmology & Visual Science (IOVS), Jg. 56, 2015, Nr. 10, S. 5854 – 5861DOI (Open Access)
-
Future perspectives in melanoma research : meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014In: Journal of Translational Medicine, Jg. 13, 2015, Nr. 1, S. 374DOI (Open Access)
-
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaIn: Science, Jg. 350, 2015, Nr. 6257, S. 207 – 211DOI, Online Volltext (Open Access)
-
Kikuchi-Fujimoto-Syndrom und adulter Morbus Still : eine seltene KoinzidenzIn: Der Hautarzt, Jg. 66, 2015, Nr. 12, S. 940 – 944
-
Modulation and apoptosis of neutrophil granulocytes by extracorporeal photopheresis in the treatment of chronic graft-versus-host diseaseIn: PLoS ONE, Jg. 10, 2015, Nr. 8, S. e0134518DOI (Open Access)
-
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal MelanomaIn: PLoS ONE, Jg. 10, 2015, Nr. 3, S. e0118564DOI (Open Access)
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.In: Annals of Oncology, Jg. 26, 2015, Nr. 1, S. 250 – 251
-
Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathwayIn: OncoTarget, Jg. 6, 2015, Nr. 34, S. 36041 – 36052DOI (Open Access)
-
The Mechanism of Type I Interferon-Mediated Polarization of Tumor-Associated Neutrophils in Mice and HumanIn: Blood, Jg. 126, 2015, Nr. 23
-
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaIn: Annals of Oncology, Jg. 25, 2014, Nr. 3, S. 747 – 753
-
Future perspectives in melanoma research : meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013In: Journal of Translational Medicine, Jg. 12, 2014, Nr. 1, S. 277DOI (Open Access)
-
Genetic and clinico-pathologic analysis of metastatic uveal melanomaIn: Modern Pathology, Jg. 27, 2014, Nr. 2, S. 175 – 183
-
Genetic evolution of T-cell resistance in the course of melanoma progressionIn: Clinical Cancer Research, Jg. 20, 2014, Nr. 24, S. 6593 – 6604
-
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma : Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cellsIn: Clinical Cancer Research, Jg. 20, 2014, Nr. 6, S. 1601 – 1609
-
Open randomised prospective comparative multi-centre intervention study of patients with Cystic fibrosis and early diagnosed diabetes mellitusIn: BMC Pediatrics, Jg. 14, 2014, Nr. 1, S. 70DOI (Open Access)
-
Statin use and its effect on all-cause mortality of melanoma patients : a population-based Dutch cohort studyIn: Cancer Medicine, Jg. 3, 2014, Nr. 5, S. 1284 – 1293DOI (Open Access)
-
TERT promoter mutation status as an independent prognostic factor in cutaneous melanomaIn: Journal of the National Cancer Institute (JNCI), Jg. 106, 2014, Nr. 9
-
TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomasIn: Modern Pathology, Jg. 27, 2014, Nr. 4, S. 502 – 508DOI (Open Access)
-
Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicityIn: Journal of Clinical Oncology (JCO), Jg. 31, 2013, Nr. 30, S. 3844 – 3845
-
Conjunctival Melanomas Harbor BRAF and NRAS Mutations—ResponseIn: Clinical Cancer Research, Jg. 19, 2013, Nr. 22, S. 6331 – 6332
-
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomasIn: Clinical Cancer Research, Jg. 19, 2013, Nr. 12, S. 3143 – 3152
-
Cutting edge : an inactive chromatin configuration at the IL-10 locus in human neutrophilsIn: The Journal of Immunology (JI), Jg. 190, 2013, Nr. 5, S. 1921 – 1925
-
Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancerIn: Clinical Cancer Research, Jg. 19, 2013, Nr. 23, S. 6585 – 6596
-
IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cellsIn: PLoS ONE, Jg. 8, 2013, Nr. 2, S. e47234DOI (Open Access)
-
Immunological consequences of selective BRAF inhibitors in malignant melanoma : Neutralization of myeloid-derived suppressor cellsIn: OncoImmunology, Jg. 2, 2013, Nr. 8, e25218DOI (Open Access)
-
Kombination von BRAF-Inhibitoren (BRAFi) und zerebraler Bestrahlung bei Patienten mit metastasiertem Melanom : Eine mögliche Behandlungsoption für neu aufgetretene oder pro-grediente Hirnmetastasen unter Therapie mit BRAF-InhibitorenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG), Jg. 11, 2013, Nr. 9, S. 952 – 952
-
Lack of SF3B1 R625 mutations in cutaneous melanomaIn: Diagnostic Pathology, Jg. 8, 2013, S. 87DOI (Open Access)
-
Reduced frequency of CD56 dim CD16 pos natural killer cells in pediatric systemic inflammatory response syndrome/sepsis patientsIn: Pediatric Research, Jg. 74, 2013, Nr. 4, S. 427 – 432
-
TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinomaIn: PLoS ONE, Jg. 8, 2013, Nr. 11, S. e80354DOI (Open Access)
-
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumoursIn: British Journal of Cancer (BJC), Jg. 109, 2013, Nr. 2, S. 497 – 501DOI (Open Access)
-
Vemurafenib reverses immunosuppression by myeloid derived suppressor cellsIn: Cancer Research, Jg. 73, 2013, Nr. 8 Suppl., S. 4714
-
Vemurafenib reverses immunosuppression by myeloid derived suppressor cellsIn: International Journal of Cancer, Jg. 133, 2013, Nr. 7, S. 1653 – 1663
-
Gegen den Hautkrebs : Forschung zur Überwindung immuntherapeutischer Hürden beim malignen MelanomIn: Unikate: Berichte aus Forschung und Lehre, 2012, Nr. 42: Translationale Krebsforschung: Auf dem Weg zu neuen Therapien, S. 32 – 41DOI, Online Volltext (Open Access)
-
IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment modelIn: Journal of Molecular Medicine, Jg. 90, 2012, Nr. 2, S. 139 – 147DOI (Open Access)
-
IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patientsIn: Cancer Immunology, Immunotherapy, Jg. 61, 2012, Nr. 9, S. 1395 – 1405
-
Induced and natural regulatory T cells in human cancerIn: Expert Opinion on Biological Therapy, Jg. 12, 2012, Nr. 10, S. 1383 – 1397
-
Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samplesIn: Journal of Immunological Methods, Jg. 381, 2012, Nr. 1-2, S. 14 – 22
-
Phenotypic and functional characteristics of CD4⁺CD39⁺ FOXP3⁺ and CD4⁺CD39⁺FOXP3ⁿeg T-cell subsets in cancer patientsIn: European Journal of Immunology, Jg. 42, 2012, Nr. 7, S. 1876 – 1885
-
Dendritic cell generation and CD4+CD25HIGHFOXP3+regulatory regulatory t cells in human head and neck carcinoma during radio-chemotherapyIn: European Journal of Medical Research, Jg. 16, 2011, Nr. 2, S. 57 – 62DOI (Open Access)
-
Separation of human CD4⁺CD39⁺ T cells by magnetic beads reveals two phenotypically and functionally different subsetsIn: Journal of Immunological Methods, Jg. 369, 2011, Nr. 1-2, S. 59 – 68
-
Adjuvant pegylated interferon α-2b therapy for melanomaIn: Oncology Letters, Jg. 1, 2010, Nr. 2, S. 237 – 241
-
Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma : Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their ManagementIn: Seminars in Oncology, Jg. 37, 2010, Nr. 5, S. 485 – 498
-
Corrigendum to ‘Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data’In: European Journal of Cancer (EJC). Amsterdam: Elsevier, Jg. 123, 2019, S. 171DOI (Open Access)
-
EditorialIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 14, 2016, Nr. 1, S. 1 – 2
-
Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrenceIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 40, 2022, Nr. 16_Suppl., S. 9570DOI (Open Access)
-
REINA - Retrospective Multicenter ADOReg Evaluation of Ipilimumab plus Nivolumab in Avelumab-refractory Merkel cell carcinoma
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 21 -
Therapiemanagement des ersten Rezidivs nach adjuvanter Therapie im Stadium III : multizentrische real-world Daten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 3 -
Ipilimumab plus Nivolumab in Avelumab-refractory Merkel Cell Carcinoma : A retrospective multicenter AnalysisIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 19, 2021, Nr. Suppl. 4, S. 47 – 48
-
Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapyIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. 15_Suppl, S. 9545 – 9545DOI (Open Access)
-
Therapieentscheidung bei Indikation zur adjuvanten Therapie des Melanoms : Multizentrische Real World DataIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 18, 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV43DOI (Open Access)
-
Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance
4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, September 30 - October 3, 2018, New York, NY,In: Cancer Immunology Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 7, 2019, Nr. 2, Supplement, S. A082DOI (Open Access) -
BRAF/MEK inhibition in melanoma patients with rare BRAF mutationsIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 36, 2018, Nr. Suppl. 15, S. 9542 – 9542DOI (Open Access)
-
CCR5 Δ32 Polymorphismus als prädiktiver Marker für die Therapie mit Immuncheckpoint‐Inhibitoren beim Melanom
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 16, 2018, Nr. S6, S. 49 – 50DOI (Open Access) -
Die Anzahl mutierter Melanom‐assoziierter Gene und die Expression von PD‐L1 sind unabhängige Prädiktoren der anti‐PD1 Immuntherapie ‐ eine prospektive Registerstudie der ADO (ADOREG/TRIM)In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 16, 2018, Nr. S6, S. 7 – 8DOI (Open Access)
-
Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumorsIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 36, 2018, Nr. Suppl. 15, S. 3036DOI, Online Volltext (Open Access)
-
Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockadeIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 36, 2018, Nr. Suppl. 15, S. 3074 – 3074DOI (Open Access)
-
The influence of extracorporeal photopheresis on NF kappa signaling and cytokine expression in lung transplant patientsIn: Transplant International. Lausanne: Frontiers Media, Jg. 29, 2016, Nr. Suppl. 3, S. 42DOI (Open Access)
-
Mechanistic analysis of CD3-driven T cell functions reveals a CD32a polymorphism associated with melanoma emergenceIn: Experimental Dermatology. Hoboken: Wiley, Jg. 24, 2015, Nr. 3, 42nd Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF), March 05-07, 2015, Ulm, Germany, S. E18 – E18
-
Oncogene and copy number analysis of a larger cohort of conjunctival melanomaIn: Experimental Dermatology. Hoboken: Wiley, Jg. 22, 2013, Nr. 3, S. E43
-
Quantitation of HLA-A2-MAGE3_271-279 complexes on the DC surface improves anticancer vaccine designsIn: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 72, 2012, Nr. 8, Suppl., S. 1574
-
Die direkte und indirekte exogene Beeinflussung der anti-Tumorimmunität am Beispiel des Malignen MelanomsDuisburg, Essen, 2014
-
Suppression der LPS- und Zymosan A-induzierten Immunantwort von Makrophagen durch zerstörte Muskelzellen in vitroDuisburg, Essen, 2009
-
MAPKinase Inhibition nach Versagen einer PD-1 basierten Immuncheckpoint Blockade in Patienten:innen mit fortgeschrittenem Melanom : eine Auswertung des multizentrischen prospektiven Hautkrebsregisters ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 28 -
Management of infliximab-refractory immune checkpoint inhibitor gastrointestinal toxicity : A multicenter case series
2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) ; June 3-7, 2022, Chicago, Ill., USA and virtual,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 40, 2022, Nr. 16_Suppl.: 2022 ASCO Annual Meeting, S. 2665DOI (Open Access)